학술논문

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma
Document Type
Article
Source
In: eClinicalMedicine. (eClinicalMedicine, June 2023, 60)
Subject
Language
English
ISSN
25895370